Hypochondroplasia
Symptoms, Doctors, Treatments, Advances & More

Learn About Hypochondroplasia

What is the definition of Hypochondroplasia?

Hypochondroplasia is a form of short-limbed dwarfism. This condition affects the conversion of cartilage into bone (a process called ossification), particularly in the long bones of the arms and legs. Hypochondroplasia is similar to another skeletal disorder called achondroplasia, but the features tend to be milder.

What are the causes of Hypochondroplasia?

The vast majority of cases of hypochondroplasia are caused by variants in the FGFR3 gene. This gene provides instructions for making a protein that is involved in the development and maintenance of bone and brain tissue. Although it remains unclear how FGFR3 gene variants lead to the features of hypochondroplasia, researchers believe that these genetic changes cause the protein to be overly active. The overactive FGFR3 protein likely interferes with skeletal development and leads to the disturbances in bone growth that are characteristic of this disorder.

How prevalent is Hypochondroplasia?

The incidence of hypochondroplasia is unknown. Researchers believe that it may be about as common as achondroplasia, which occurs in 1 in 15,000 to 40,000 newborns. More than 200 people worldwide have been diagnosed with hypochondroplasia.

Is Hypochondroplasia an inherited disorder?

Hypochondroplasia is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. Most people with hypochondroplasia are born to parents who do not have the condition and are of average heights; these cases are caused by new variants in the FGFR3 gene. In the remaining cases, people with hypochondroplasia inherit an altered FGFR3 gene from one or two affected parents.  Individuals who inherit two altered copies of this gene typically have more severe problems with bone growth than those who inherit a single FGFR3 variant.

Who are the top Hypochondroplasia Local Doctors?
Elite in Hypochondroplasia
Pediatric Endocrinology
Elite in Hypochondroplasia
Pediatric Endocrinology
Referral may be required

Main Hospital-Diabetes Complex Clinic

111 Michigan Avenue Northwest, 
Washington, DC 
Languages Spoken:
English, Hebrew
Accepting New Patients
Offers Telehealth

Andrew Dauber is a Pediatric Endocrinologist practicing medicine in Washington, Washington, D.c.. Dr. Dauber is rated as an Elite provider by MediFind in the treatment of Hypochondroplasia. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Short Stature (Growth Disorders), Hypochondroplasia, Idiopathic Short Stature (ISS), and Precocious Puberty. Dr. Dauber is board certified in Endocrinology Diabetes And Metabolism: American Board Of Pediatrics, 2011 and Pediatrics: American Board Of Pediatrics, 2007. Dr. Dauber is currently accepting new patients.

Elite in Hypochondroplasia
Elite in Hypochondroplasia
Referral may be required
Paris, FR 

Laurence Mallet-Legeai practices practicing medicine in Paris, France. Mr. Mallet-Legeai is rated as an Elite expert by MediFind in the treatment of Hypochondroplasia. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Hypochondroplasia, Achondroplasia, Acanthosis Nigricans, and Acromicric Dysplasia.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hypochondroplasia
Elite in Hypochondroplasia
Referral may be required
Paris, FR 

Nabil Kaci practices practicing medicine in Paris, France. Mr. Kaci is rated as an Elite expert by MediFind in the treatment of Hypochondroplasia. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Hypochondroplasia, Achondroplasia, Acanthosis Nigricans, and Thanatophoric Dysplasia.

What are the latest Hypochondroplasia Clinical Trials?
Prospective Clinical Assessment Study in Children With Hypochondroplasia: ACCEL

Summary: This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children With Hypochondroplasia, Aged 0 to < 36 Months

Summary: The purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to \< 36 months over a 52-week period.

Who are the sources who wrote this article ?

Published Date: May 29, 2023
Published By: National Institutes of Health